These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 37603294)

  • 1. Elevated Levels of Cytotoxicity, Cytokines, and Anti-SARS-CoV-2 Antibodies in Mild Cases of COVID-19.
    Fernández-Rojas MA; Ávila G; Romero-Valdovinos M; Plett-Torres T; Salazar AM; Sordo M; Chávez-Vargas M; Coeto Ángeles CJ; Cruz-Rivera M; Santiago-Olivares C; Ramírez Hinojosa JP; Maravilla P; Flisser A; Ostrosky-Wegman P; Mendlovic F
    Viral Immunol; 2023 Oct; 36(8):550-561. PubMed ID: 37603294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.
    Servian CDP; Spadafora-Ferreira M; Dos Anjos DCC; Guilarde AO; Gomes-Junior AR; Borges MASB; Masson LC; Silva JMM; de Lima MHA; Moraes BGN; Souza SM; Xavier LE; de Oliveira DCA; Batalha-Carvalho JV; Moro AM; Bocca AL; Pfrimer IAH; Costa NL; Feres VCR; Fiaccadori FS; Souza M; Gardinassi LG; Durigon EL; Romão PRT; Jorge SAC; Coelho V; Botosso VF; Fonseca SG
    Front Immunol; 2023; 14():1206979. PubMed ID: 37876932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversity of immune responses in children highly exposed to SARS-CoV-2.
    Úbeda M; Maza MDC; Delgado P; Horndler L; Abia D; García-Bermejo L; Serrano-Villar S; Calvo C; Bastolla U; Sainz T; Fresno M
    Front Immunol; 2023; 14():1105237. PubMed ID: 36936972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
    Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
    Front Immunol; 2021; 12():723585. PubMed ID: 34489974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of anti-SARS-CoV-2 antibodies in Japanese COVID-19 patients.
    Hiki M; Tabe Y; Ai T; Matsue Y; Harada N; Sugimoto K; Matsushita Y; Matsushita M; Wakita M; Misawa S; Idei M; Miida T; Tamura N; Takahashi K; Naito T
    PLoS One; 2021; 16(4):e0249449. PubMed ID: 33822809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Observation of Immune Response for 23 Months in COVID-19 Convalescent Patients After Infection and Vaccination.
    Xu J; Zheng J; Tan Y; Cai J; Xiang Y; Ling H; Li Z; Bai Q
    Viral Immunol; 2023; 36(6):389-400. PubMed ID: 37276049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.
    Guo X; Zeng L; Huang Z; He Y; Zhang Z; Zhong Z
    Front Immunol; 2020; 11():1936. PubMed ID: 32849650
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytokine Profiles Associated With Worse Prognosis in a Hospitalized Peruvian COVID-19 Cohort.
    Pons MJ; Ymaña B; Mayanga-Herrera A; Sáenz Y; Alvarez-Erviti L; Tapia-Rojas S; Gamarra R; Blanco AB; Moncunill G; Ugarte-Gil MF
    Front Immunol; 2021; 12():700921. PubMed ID: 34539631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
    Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
    Front Immunol; 2021; 12():614436. PubMed ID: 33790892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and roles of severe acute respiratory syndrome coronavirus 2-specific antibodies in patients with different severities of coronavirus 19.
    Huang Z; Chen H; Xue M; Huang H; Zheng P; Luo W; Liang X; Sun B; Zhong N
    Clin Exp Immunol; 2020 Nov; 202(2):210-219. PubMed ID: 32706417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children.
    Sananez I; Raiden SC; Algieri SC; Uranga M; Grisolía NA; Filippo D; De Carli N; Lalla SD; Cairoli H; Chiolo MJ; Meregalli CN; Cohen E; Mosquera G; Marcó Del Pont M; Giménez LI; Gregorio G; Sarli M; Alcalde AL; Davenport C; Bruera MJ; Simaz N; Pérez MF; Nivela V; Bayle C; Alvarez L; Revetria M; Tuccillo P; Agosta MT; Pérez H; Nova SV; Suárez P; Takata EM; García M; Lattner J; Rolón MJ; Coll P; Salvatori M; Piccardo C; Russo C; Varese A; Seery V; Holgado MP; Polo ML; Ceballos A; Nuñez M; Penedo JMG; Ferrero F; Geffner J; Arruvito L
    EBioMedicine; 2021 Oct; 72():103615. PubMed ID: 34649078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
    Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
    Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients.
    Zeng F; Wu M; Wang J; Li J; Hu G; Wang L
    J Med Virol; 2021 Dec; 93(12):6506-6511. PubMed ID: 34170519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between viral load, infection-to-delivery interval and mother-to-child transfer of anti-SARS-CoV-2 antibodies.
    Poon LC; Leung BW; Ma T; Yu FNY; Kong CW; Lo TK; So PL; Leung WC; Shu W; Cheung KW; Moungmaithong S; Wang CC
    Ultrasound Obstet Gynecol; 2021 Jun; 57(6):974-978. PubMed ID: 33798280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical).
    Ghofrani Nezhad M; Jami G; Kooshkaki O; Chamani S; Naghizadeh A
    J Interferon Cytokine Res; 2023 Apr; 43(4):147-163. PubMed ID: 37062817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19.
    Codina H; Vieitez I; Gutierrez-Valencia A; Skouridou V; Martínez C; Patiño L; Botero-Gallego M; Trujillo-Rodríguez M; Serna-Gallego A; Muñoz-Muela E; Bobillo MM; Pérez A; Cabrera-Alvar JJ; Crespo M; O'Sullivan CK; Ruiz-Mateos E; Poveda E
    Microorganisms; 2021 Oct; 9(11):. PubMed ID: 34835384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kinetics of viral load and antibodies to SARS-CoV-2.
    Sun J; Tang X; Bai R; Liang C; Zeng L; Lin H; Yuan R; Zhou P; Huang X; Xiong Q; Peng J; Cui F; Ke B; Su J; Liu Z; Lu J; Tian J; Sun R; Ke C
    Clin Microbiol Infect; 2020 Dec; 26(12):1690.e1-1690.e4. PubMed ID: 32898715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.